Skip to main content
Caplight Logo









Elion Therapeutics

Elion Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://eliontx.com/

Last Round

Series B

Jun 17, 2024

Est. Valuation

$163M

Total Funding Raised

$81M

Company Overview

Elion Therapeutics is a biotechnology company that develops next-generation polyene antifungal therapies to treat life-threatening invasive fungal infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antifungal therapyinvasive mould infectionbiopharmaceuticalclinical-stage biotechsmall-molecule drugdrug discoveryclinical trialpharma pipelineantifungal drugbiotech startuptherapeutic asset

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elion Therapeutics Comparables

Compare Elion Therapeutics with similar companies based on industry and business-model similarity.

Elion Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
F2G
83%
Matinas BioPharma Holdings, Inc.
81%
Appili Therapeutics Inc.
79%

Elion Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 17, 2024
SeedJan 1, 2019

Key People

Founding team and executive leadership

Kieren Marr

President Chief Executive Officer

Executive Team

Anjeza Gjino

Interim Chief Financial Officer

Executive Team

Elion Therapeutics Investors

Notable investors and investment history

Elion Therapeutics investors
InvestorRounds
Deerfield ManagementSeed, Series A, Series B
AMR Action FundSeries B
University of Illinois FoundationSeries B
Illinois VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Phase 2 study started for Turletricin (EL219) for invasive mould infections.

  • Jun 17, 2024

    $81M round led by Deerfield Management

Elion Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elion Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elion Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range18
Year Founded2017
Last FundingJun 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?